Posts

Showing posts with the label Socialissues

Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccines

Image
[ad_1] Moderna Covid-19 Vaccine mRNA 2024-2025 formula. Courtesy: Moderna A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. It's that time of the year again. A new round of Covid shots is on its way to Americans.  The Food and Drug Administration last week approved updated mRNA-based vaccines from Pfizer and Moderna amid a relatively large summer surge of the virus. Here's what you need to know, including how the shots are different this time around, who is eligible, where to get a vaccine and more.  What makes these shots different? U.S. health officials have long told patients to expect annual updates to Covid shots as the virus mutates into new strains that can dodge the immunity people develop from previous vaccinations or infections. It's similar to how the U.S. rolls out new flu shots each year.  This time, the shots fro...

Supreme Court blocks restrictions on Biden administration efforts to remove contentious social media posts

Image
[ad_1] The US Supreme Court in Washington, DC, on June 27, 2023. Kevin Dietsch | Getty Images WASHINGTON — The Supreme Court on Friday blocked in full a lower court ruling that would have curbed the Biden administration's ability to communicate with social media companies about contentious content on such issues as Covid-19. The decision in a  short unsigned order  puts on hold a Louisiana-based judge's ruling in July that specific agencies and officials should be barred from meeting with companies to discuss whether certain content should be stifled. The Supreme Court also agreed to immediately take up the government's appeal, meaning it will hear arguments and issue a ruling on the merits in its current term, which runs until the end of June. Three conservative justices noted that they would have denied the application: Samuel Alito, Clarence Thomas and Neil Gorsuch. "At this time in the history of our country, what the court has done, I fear, will be seen by so...

Healthy Returns: Higher medical costs are pinching insurers

Image
[ad_1] A UnitedHealth Group health insurance card is seen in a wallet, Oct.14, 2019. Lucy Nicholson | Reuters Good afternoon! Health insurers are feeling the squeeze as older patients head to the doctor more than expected. CVS , which owns health insurer Aetna, on Wednesday  slashed its full-year profit outlook , citing the potential for higher medical costs to bite into its profits. That warning came two weeks after insurance giant  Humana  cited the same factor as it issued a  dismal 2024 earnings guidance . Medical costs from Medicare Advantage patients have  spiked over the last year  as more older adults return to hospitals to undergo procedures they had delayed during the Covid pandemic, such as joint and hip replacements.  Medicare Advantage , a type of privately run health insurance plan contracted by Medicare, has long been a key source of growth and profits for the insurance industry.  More than half  of Medicare beneficiaries are enrolled in such plans, enticed by lower...

Senators launch bipartisan probe of private equity's growing role in U.S. health care

Image
[ad_1] Two U.S. senators have launched a bipartisan investigation into secretive and powerful private-equity firms' involvement in health care in the nation, demanding documents and information from executives associated with two hospital systems to assess how much profit they have generated through their complex financial arrangements and whether the deals harmed patients and clinicians.   Sheldon Whitehouse, the Rhode Island Democrat who chairs the Senate Budget Committee, and Chuck Grassley, the Iowa Republican who is the committee's ranking member, are spearheading the inquiry. It began in March when Grassley requested information from private-equity giant Apollo Global Management , owner of Ottumwa Regional Health Center, a Lifepoint Health facility in southeast Iowa where a  male nurse assaulted  at least nine sedated patients in 2021 and 2022. The nurse later died from an overdose at the facility. "When it comes to our nation's hospitals, a business model t...

The U.S. has high maternal mortality rates — and it has gotten worse for Latinas

Image
[ad_1] Zaza Cristina Robles worked as a pregnancy coach in her native Peru, so when she arrived in the U.S. at 16 weeks pregnant, the first thing she did after settling in with her in-laws was to seek medical care. "When they showed us the bill, it was so expensive, my husband and I thought, 'If this is just for the doctor's visit, imagine what the delivery will be?' It scared us," she said. Her sister-in-law put her in touch with the Hispanic Health Council, a nonprofit in Hartford, Connecticut. The organization's Comadrona — or midwife — program helps Latina immigrants and low-income pregnant women navigate the complications of the U.S. health-care system. "They really helped clear up a lot of my fears," Robles said. The program helped Robles gain health-care coverage as she and her husband seek asylum in the United States. Her comadrona helped her find a doctor who treats low-income patients and connected her with other services. "One of...

FDA advisors recommend AstraZeneca, Sanofi antibody to protect babies from RSV

Image
[ad_1] A panel of independent advisors to the Food and Drug Administration unanimously recommended Thursday that the antibody nirsevimab be approved for use to protect infants from respiratory syncytial virus , the leading cause of hospitalization among newborns. If the FDA approves nirsevimab, the antibody would become the first medical intervention available in the U.S. that can protect all infants from RSV . The FDA, which is not obligated to follow the recommendation of its advisory panel, is expected to make a final decision on nirsevimab in the third quarter. Nirsevimab is a monoclonal antibody made by AstraZeneca . The medication would be marketed by Sanofi . The advisory panel voted 21-0 to recommend its approval. In a separate vote, the advisors also recommended nirsevimab's use in children up to 2 years old who remain vulnerable to the virus in their second RSV season. That vote was 19-2. RSV kills nearly 100 babies in the United States every year, according to sci...

Biden administration examining role of supply chain middlemen in generic drug shortages

Image
[ad_1] A variety of generic pills and capsules.  Nenov | Moment | Getty Images The Federal Trade Commission on Wednesday said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account for the majority of Americans' prescriptions. The move follows an unprecedented shortfall of crucial medicine ranging from injectable cancer therapies to generics, or cheaper versions of brand-name medicines, over the last year, which has forced hospitals and patients to ration drugs. Problems from manufacturing quality control to demand surges can drive supply issues. But the Biden administration is zeroing in on other players in the drug supply chain to uncover the "root causes and potential solutions" to ongoing shortages.  In a joint request for information, the FTC and the Department of Health and Human Services are seeking public comment on the contracting practices, m...

Medicare pricing deal set to play a key role in Biden's 2024 campaign pitch

Image
[ad_1] U.S. President Joe Biden speaks about lowering health-care costs, in the East Room of the White House in Washington, D.C., Aug. 29, 2023. Saul Loeb | AFP | Getty Images WASHINGTON — President Joe Biden is placing a priority on reducing individual health-care costs as he seeks reelection in a country where medical spending accounts for 18.3% of the nation's gross domestic product, according to the Centers for Medicare and Medicaid Services. "Boy, we've been fighting Big Pharma for a long time," Biden said Tuesday from the White House. "I promise you I'm gonna have your back and I'll never stop fighting for you on this issue, nor will Kamala." On Tuesday, the White House announced 10 prescription drugs that will be subject to the first-ever Medicare price negotiations, which will go into effect in 2026. The 10 medicines accounted for $50.5 billion, or about 20%, of total Part D prescription drug costs   between June 1, 2022, and May 31, ...

Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action

Image
[ad_1] Sen. Bernie Sanders (I-VT) arrives to the U.S. Capitol Building on June 01, 2023 in Washington, DC. Anna Moneymaker | Getty Images Sen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to ensure seniors can actually afford the expensive Alzheimer's treatment Leqembi . Sanders, who chairs the Senate Health Committee, in a letter to HHS Secretary Xavier Becerra called the $26,500 annual price tag for Leqembi set by drugmakers Eisai and Biogen "unconscionable." The Vermont independent said the drug's current cost would put a substantial financial burden on Medicare and increase premiums for seniors. Medicare is the federal program that provides health coverage to primarily older Americans. Sanders said the "outrageously high price" of Leqembi "will prevent seniors who need this drug from receiving treatment." The lawmaker wrote that HHS should use its authority to break Leqembi's pa...

Appeals court imposes restrictions on abortion pill, but drug will stay on the market for now

Image
[ad_1] A container holding boxes of Mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women's Clinic in Carbondale, Illinois, April 20, 2023. Evelyn Hockstein | Reuters A federal appeals court on Wednesday imposed restrictions on the abortion pill mifepristone, though the ruling will not have an immediate impact. The order by the U.S. 5th Circuit Court of Appeals is almost certain to be appealed to the Supreme Court. Justice Samuel Alito in April preemptively paused any ruling from the appeals court pending a petition for the high court to take the case. If the Supreme Court does not take the case, the restrictions will go into effect. Should the restrictions go in to effect, women would no longer be able to obtain the abortion by mail. Patients would have to receive a prescription from a doctor and have follow-up appointments in person. The restrictions would also shorten the time period when women can take the pill to 49 days into t...

Picking health insurance can be tricky: 6 key terms to know as open enrollment starts

Image
[ad_1] Sdi Productions | E+ | Getty Images Many people will soon be picking their health insurance plans for 2024: November is a common month for workplace open enrollment, and the public marketplace opens Nov. 1. But choosing a health plan can be tricky. In fact, a 2017 study found many people lose money due to suboptimal choices: Sixty-one percent chose the wrong plan, costing them an average $372 a year. The paper, authored by economists at Carnegie Mellon University and the Wisconsin School of Business, examined choices made by almost 24,000 workers at a U.S. firm. More from Personal Finance: 'Cash stuffing' may forgo 'easiest money' you can make These credit cards have had 'increasingly notable' high rates Home 'affordability is incredibly difficult,' economist says Health plans have many moving parts, such as premiums and deductibles. Each has financial implications for buyers. "It is confusing, and people have no idea how much they ...

Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says

Image
[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a Centers for Disease Control and Prevention analysis .  A CDC medical officer presented the analysis, conducted by researchers at the University of Michigan, at an advisory committee meeting on Wednesday. The committee recommended that adults ages 60 and older may receive one dose of Pfizer's or GSK's respiratory syncytial virus shot after consulting their doctor.  The analysis found that vaccinating one million adults 65 and older with a single dose of Pfizer's shot may prevent 2,500 hospitalizations and 25,000 outpatient visits over two seasons of the virus. RSV season typically lasts from October to March in the Northern Hemisphere.   The analysis also found that vaccinating one million adults in the same age gr...